Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oxaliplatin + sorafenib in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after cisplatin-based therapy
2008-004223-27Phase 2Active
- Sponsor
- GEMCAD
- Start
- Sep 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by GEMCAD. Primary endpoint: Progression-free survival. Started Sep 2008; status: active.
02
Drugs
sorafeniboxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2008-004223-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004223-27.